Status
Conditions
Treatments
About
Glucocerebrosidase (GBA) mutations are the most common risk factor for Parkinson's Disease (PD). GBA-related PD(GBA-PD) exhibits a more malignant phenotype as compared to no-carriers. Still, the mechanisms behind the increased malignancy in GBA-PD are not well understood. The definition of biomarkers able to stratify PD clinical trajectories in PD is therefore crucial to identify effective treatments and support diagnosis.The investigators will examine the role of GBA-mutations in accelerating a-synuclein (a-syn) and synaptic pathologies in PD by combining neuroimaging (positron emission tomography-PET), biochemical and clinical features. This will illuminate the pathophysiology underlying GBA-mutations in PD and identify biomarkers for the malignant PD phenotype. Also, the investigators will combine longitudinal clinical and imaging/biochemical features to define a prognostic algorithm for predicting disease faster progression in GBA-PD and monitoring disease trajectories in unaffected GBA carriers.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
There are currently no registered sites for this trial.
Central trial contact
Cinzia Fattore; Micol Avenali
Start date
Apr 30, 2023 • 2 years ago
End date
Dec 12, 2024 • 4 months ago
Today
May 09, 2025
Lead Sponsor
Collaborating Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal